Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 1/20 | 0.43 |
| ▸ | IL2 | P60568 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GBA1 | P04062 | 2/20 | 0.31 |
| ▸ | GLS | O94925 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23278432 | 0.89 | TTR (0.43) | TTRIL2GAA | |
| SCHEMBL22452432 | 0.85 | TTR (0.46) | TTRIL2GAAGLS | |
| SCHEMBL25671065 | 0.85 | TTR (0.44) | TTRIL2GAAGLS | |
| SCHEMBL23425576 | 0.85 | TTR (0.47) | TTRIL2ALDH1A1GBA1HPGD | |
| SCHEMBL18193660 | 0.82 | TTR (0.44) | TTRIL2GAAALDH1A1HPGD | |
| SCHEMBL24380612 | 0.79 | TTR (0.43) | TTRIL2GAAALDH1A1HPGD | |
| SCHEMBL30645075 | 0.78 | TTR (0.52) | TTRIL2GBA1 | |
| SCHEMBL18912653 | 0.76 | TTR (0.36) | TTRIL2 | |
| SCHEMBL17011377 | 0.75 | TTR (0.56) | TTRIL2ALDH1A1GBA1HPGD | |
| SCHEMBL18772725 | 0.74 | TTR (0.55) | TTRIL2GBA1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10322193-B1 | Immunoconjugates with an intracellularly-cleavable linkage | IMMUNOMEDICS, INC. (US) | 2019-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10322193-B1 | Immunoconjugates with an intracellularly-cleavable linkage | CD47, CD44, DNPEP | TTR 4028/4885IL2 322/4885GAA 251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.